Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology

Expert Opinion on Biological Therapy

Volumn 13, Issue 12, 2013, Pages 1639-1641

  Wang, David B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid; Abeta; Adjuvant; Alzheimer's disease; Microglia; Monophosphoryl lipid A; MPL; Phagocytosis; TLR4; Toll like receptors

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; IMMUNOLOGICAL ADJUVANT; LIPOPOLYSACCHARIDE; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELL ACTIVATION; COGNITION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; INFLAMMATION; MICROGLIA; MONOTHERAPY; NONHUMAN; PHAGOCYTOSIS; REVIEW; TRANSGENIC MOUSE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; ANIMALS; HUMANS; LIPID A; LIPOPOLYSACCHARIDES; MICE; TOLL-LIKE RECEPTOR 4;

EID: 84887978435     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.838556     Document Type: Review

References (15)

1. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992;256(5054):184-5
2. Herrmann N, Chau SA, Kircanski I, Lanctôt K. Current and emerging drug treatment options for Alzheimer's disease: A systematic review. Drugs 2011;71(15):2031-65
3. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-Amyloid in alzheimer's disease. Science 2010;330(6012):1774
4. Lemere CA, Masliah E. Can alzheimer disease be prevented by amyloid-[beta] immunotherapy? Nat Rev Neurol 2010;6(2):108-19
5. Rickman LS, Wistar R Jr, Hoffman SL, et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 1991;337(8748):998-1001
6. McKeage K, Romanowski B. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix). BioDrugs 2011;25(4):265-9
7. Qureshi N, Mascagni P, Ribi E, Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J Biol Chem 1985;260(9):5271-8
8. Michaud J-P, Hallé M, Lampron A, et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc Natl Acad Sci 2013;110(5):1941-6
9. Mata-Haro V, Cekic C, Martin M, et al. The vaccine adjuvant monophosphoryl lipid a as a TRIF-biased agonist of TLR4. Science 2007;316(5831):1628-32
10. Chen G, Chen KS, Kobayashi D, et al. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci 2007;27(10):2654-62
11. Kofler J, Lopresti B, Janssen C, et al. Preventive immunization of aged and juvenile non-human primates to beta-amyloid. J Neuroinflammation 2012;9(1):84
12. Tayeb H, Murray E, Price B, Tarazi F. Bapineuzumab and solanezumab for Alzheimer's disease: Is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther 2013;13(7):1075-84
13. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of alzheimer's disease. Neurology 1992;42(3):631
14. Lee DC, Rizer J, Hunt JB, et al. Review: Experimental manipulations of microglia in mouse models of Alzheimer's pathology: Activation reduces amyloid but hastens tau pathology. Neuropathol Appl Neurobiol 2013;39(1):69-85
15. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372(9634):216-23